))
Interview with Fabio Rosa, Co-Founder and Head of Research of Asgard Therapeutics
Manage episode 463832448 series 3514615
Contenido proporcionado por EIC Scaling Club. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente EIC Scaling Club o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
In this interview, Fabio Rosa, Co-Founder and Head of Research at Asgard Therapeutics, discusses their groundbreaking cancer therapy, AT108, which reprograms cancer cells into immune cells. Asgard has raised €30 million in Series A funding and is preparing for clinical trials by 2027. With strong scientific validation and key publications, the company is now focused on partnerships, production scaling, and investor relations to drive its innovative therapy forward.
30 episodios
Compartir
